FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Economic evaluation as a tool in emerging technology assessment

Thumbnail
2018
Economic_evaluation_as_pub_2018.pdf (363.7Kb)
Authors
Bogavac-Stanojević, Nataša
Article (Published version)
Metadata
Show full item record
Abstract
Medical technologies are part of health technologies and they include medical devices (MD) and in vitro diagnostics (IVD). They have become a vital part of modern healthcare. Framework for introduction of new technology in the healthcare system includes a few steps: analytical and clinical accuracy assessment, clinical utility determination and economic evaluation. In addition, payers are interested whether new technology is adequate for reimbursement. There are fairly enough specific guidelines for implementation of economic methods at the early stage of IVD development. Searching the available literature in this field, this paper discusses the economic evaluations of emerging medical technologies with focus on point of care testing (POCT) and genetic testing. Results of POCT economy studies depend on investigated perspective (payers, policy makers or society), used effectiveness values (utility, effectiveness or con-sequence estimated as monetary value) and understanding of clinical ...pathway. There is a need for better understanding of the care pathway, resource utilisation and how they change with the introduction of POCT. Introduction of genetic testing before drug therapy was recommended with the aim to improve treatment benefit and to reduce costs of adverse drug reaction. Clinical utility and cost-effectiveness analyses should be considered for novel genetic testing-guided treatments. Most of the studies considering genetic testing-guided treatments showed that those combinations were cost-saving or cost-effective compared to standard care. For medical tehnology there is no universal guidance for outcomes measurement, cost calculation, performance requirements, use of a certain type of economic studies and economic thresholds.

Keywords:
Economic evaluations / Genetic testing / In vitro diagnostics / Point of care testing
Source:
Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 3, 196-200
Publisher:
  • International Federation of Clinical Chemistry and Laboratory Medicine
Funding / projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)

ISSN: 1650-3414

Scopus: 2-s2.0-85057566740
[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_farfar_3104
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3104
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3104
AB  - Medical technologies are part of health technologies and they include medical devices (MD) and in vitro diagnostics (IVD). They have become a vital part of modern healthcare. Framework for introduction of new technology in the healthcare system includes a few steps: analytical and clinical accuracy assessment, clinical utility determination and economic evaluation. In addition, payers are interested whether new technology is adequate for reimbursement. There are fairly enough specific guidelines for implementation of economic methods at the early stage of IVD development. Searching the available literature in this field, this paper discusses the economic evaluations of emerging medical technologies with focus on point of care testing (POCT) and genetic testing. Results of POCT economy studies depend on investigated perspective (payers, policy makers or society), used effectiveness values (utility, effectiveness or con-sequence estimated as monetary value) and understanding of clinical pathway. There is a need for better understanding of the care pathway, resource utilisation and how they change with the introduction of POCT. Introduction of genetic testing before drug therapy was recommended with the aim to improve treatment benefit and to reduce costs of adverse drug reaction. Clinical utility and cost-effectiveness analyses should be considered for novel genetic testing-guided treatments. Most of the studies considering genetic testing-guided treatments showed that those combinations were cost-saving or cost-effective compared to standard care. For medical tehnology there is no universal guidance for outcomes measurement, cost calculation, performance requirements, use of a certain type of economic studies and economic thresholds.
PB  - International Federation of Clinical Chemistry and Laboratory Medicine
T2  - Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine
T1  - Economic evaluation as a tool in emerging technology assessment
VL  - 29
IS  - 3
SP  - 196
EP  - 200
UR  - https://hdl.handle.net/21.15107/rcub_farfar_3104
ER  - 
@article{
author = "Bogavac-Stanojević, Nataša",
year = "2018",
abstract = "Medical technologies are part of health technologies and they include medical devices (MD) and in vitro diagnostics (IVD). They have become a vital part of modern healthcare. Framework for introduction of new technology in the healthcare system includes a few steps: analytical and clinical accuracy assessment, clinical utility determination and economic evaluation. In addition, payers are interested whether new technology is adequate for reimbursement. There are fairly enough specific guidelines for implementation of economic methods at the early stage of IVD development. Searching the available literature in this field, this paper discusses the economic evaluations of emerging medical technologies with focus on point of care testing (POCT) and genetic testing. Results of POCT economy studies depend on investigated perspective (payers, policy makers or society), used effectiveness values (utility, effectiveness or con-sequence estimated as monetary value) and understanding of clinical pathway. There is a need for better understanding of the care pathway, resource utilisation and how they change with the introduction of POCT. Introduction of genetic testing before drug therapy was recommended with the aim to improve treatment benefit and to reduce costs of adverse drug reaction. Clinical utility and cost-effectiveness analyses should be considered for novel genetic testing-guided treatments. Most of the studies considering genetic testing-guided treatments showed that those combinations were cost-saving or cost-effective compared to standard care. For medical tehnology there is no universal guidance for outcomes measurement, cost calculation, performance requirements, use of a certain type of economic studies and economic thresholds.",
publisher = "International Federation of Clinical Chemistry and Laboratory Medicine",
journal = "Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine",
title = "Economic evaluation as a tool in emerging technology assessment",
volume = "29",
number = "3",
pages = "196-200",
url = "https://hdl.handle.net/21.15107/rcub_farfar_3104"
}
Bogavac-Stanojević, N.. (2018). Economic evaluation as a tool in emerging technology assessment. in Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine
International Federation of Clinical Chemistry and Laboratory Medicine., 29(3), 196-200.
https://hdl.handle.net/21.15107/rcub_farfar_3104
Bogavac-Stanojević N. Economic evaluation as a tool in emerging technology assessment. in Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine. 2018;29(3):196-200.
https://hdl.handle.net/21.15107/rcub_farfar_3104 .
Bogavac-Stanojević, Nataša, "Economic evaluation as a tool in emerging technology assessment" in Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 29, no. 3 (2018):196-200,
https://hdl.handle.net/21.15107/rcub_farfar_3104 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB